Okpo Health - Früherkennung bei Prostatakrebs ?

Risiko sollte bald ein Approved (Die FDA Zulassung ) für Rayaldee kommen geht es munter weiter hier. Sollte längere zeit nix kommen oder die Zulassung kommt nicht, kann es durchaus wieder auf 8 oder 9 Dollar gehen... Ist meine Einschätzung.

Auf jeden Fall bleibt es spannend, meiner Meinung nach entsteht hier ein Pharma Konzern...Rückschläge kann es immer Mal geben. Wer vor fünf Jahren auf Dr. Frost gesetzt hat seinen tenbagger.

Hoff ich konnte behilflich sein..

Vlg
Spaet  

First Call Rating Update on Opko Health Inc.

http://stafforddaily.com/...-rating-update-on-opko-health-inc/321268/

Opko Health Inc. (NYSE:OPK) has received a Strong Buy rating from First Call Corporation, a division of Thomson Reuters. The rating information was disclosed in the equity research recommendation.

Analysts from various Brokerage Firms have rated the company and commented on its price target. Opko Health Inc. (NYSE:OPK): 4 Analyst have given the stock of Opko Health Inc. (NYSE:OPK) a near short term price target of $11.88. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $1.93. The higher price target estimate is at $15 while the lower price estimates are fixed at $10.
 

July 22, 2014
OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE

http://investor.opko.com/releasedetail.cfm?ReleaseID=861206


OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints

http://www.opkorenal.com/news/second_rayaldee_trial_endpoints.html
https://translate.google.de/...points.html&edit-text=&act=url
 

OPKO Health, Inc. OPK 0.35% today announced the launch of the 4Kscore® test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S. and European launch of the 4Kscore test in 2014.

The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer. The test was developed and validated by OPKO in a 1,012 patient blinded, prospective study in the United States in 2014. The results of this validation trial were published in the journal European Urology and presented at the 2014 Congress of the Mexican Society of Urology by one of the publication's authors, Dr. Sanoj Punnen, of the University of Miami.

Read more: http://www.benzinga.com/news/15/01/5187405/...in-mexico#ixzz3Q9ghGv8V
 

Neues Allzeithoch

OPKO Health Inc.(NYSE:OPK) and Pfizer Inc. (NYSE: PFE) today announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP a long-acting human growth hormone. The closing follows termination of the waiting period under the Hart-Scott Rodino Act.

More: http://www.pharmiweb.com/pressreleases/...#.VMqtOi4m8mc#ixzz3QFZwjwZf
 

http://investor.opko.com/events.cfm  

Opko Health Inc's Vice Chairman & CTO just picked up 7,323,754 shares

http://www.sec.gov/Archives/edgar/data/944809/...-15-008082-index.htm

Opko Health CEO Buys $169,050.00 in Stock (OPK)

http://www.wkrb13.com/markets/477260/...-buys-169050-00-in-stock-opk/  

auch etwas und zwar Gewinnmitnahmen. Der Wert ist lange Zeit gut gelaufen und vielleicht bald die Möglichkeit für Neueinsteiger für einen Einstieg....  

von Teva zurück

Opko Health And Teva Pharmaceutical
ndustries Surge Following Chairman's Resignation

Shares of Opko Health Inc. OPK 3.99% and Teva Pharmaceutical Industries Ltd (ADR) TEVA 1.81% surged following the resignation of Teva’s Chairman.

Dr. Phillip Frost resigned from the Teva Pharmaceutical Industries Board of Directors, effective February 4, 2015, and Professor Yitzhak Peterburg assumed the role of Chairman.

Read more: http://www.benzinga.com/news/15/02/5215314/...-resignat#ixzz3QtMKNSGL
 

The resignation of prominent healthcare investor/entrepreneur Dr. Phillip Frost, M.D., from Teva Pharmaceutical Industries' (TEVA +1.8%) Board of Directors prompts aggressive buying from speculators who think a potential deal is afoot with Opko Health (OPK +4.6%). Teva is up on 50% higher volume while Opko's turnover is 3x average.



http://seekingalpha.com/news/...oard-member-stokes-speculative-buying  

noch keinem geschadet meine ertradeten Shares behalte ich...  

Könnte eine etwas größere Korrektur werden

http://www.rockhilldaily.com/...ecords-biggest-short-position/337416/  

da hast aber einen guten Riecher gehabt. Klasse  

Ellogo würde mich freuen :-)  

nicht genug Shares bekommen. Und kauft weiter Agressiv nach..

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock in a transaction that occurred on Friday, February 13th. The stock was purchased at an average price of $13.61 per share, for a total transaction of $340,250.00. Following the acquisition, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $27,388,450.97. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

http://www.sec.gov/Archives/edgar/data/898860/.../xslF345X01/doc4.xml  

Habe keine Aktien gekauft und somit auch nichts verdient.
Aber macht ja nix, man kann ja nicht immer dabei sein ;-)  

Billionaire Frost Is Flab’s New Enemy With Diet Drug Bet

http://www.bloomberg.com/news/articles/2015-02-04/...th-diet-drug-bet


https://translate.google.de/...et-drug-bet&edit-text=&act=url  

Eine monatliche Spritze gegen Übergewicht. Das Medikament ist aber erst in Phase 1 .

Heute freue ich mich natürlich das die 15 $ Marke geknackt wurde mal sehen was  nächste Woche ist, da kommen die Quartalszahlen. Normalerweise sollte sich der
Pfizer-deal schon positv auswirken. Aber was ist mit dem 4-Score test, der schon ein halbes Jahr läuft ?


Mar 2, 2015
Q4 2014 OPKO Health Inc Earnings Release (Estimated) Add to calendar
 

OPKO To Announce Fourth Quarter And Full Year 2014 Financial Results On February 27, 2015

http://www.thestreet.com/story/13060073/1/...on-february-27-2015.html

OPKO Health, Inc. (NYSE: OPK) will announce fourth quarter and full year 2014 financial results on Friday, February 27, after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business update and discuss its results in greater detail at 8:30 a.m. ET on Monday, March 2, 2015.

The conference call will be available via phone and webcast. The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. A link to the live webcast is also included below.  

OPKO Announces Fourth Quarter Operating and Financial Results

http://investor.opko.com/releasedetail.cfm?ReleaseID=898976

   Pfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015; OPKO Received $295 Million of $570 Million Total Potential Up Front and Milestone Payments
   RayaldeeTM New Drug Application (NDA) Submission Planned for Q1 2015
   Positive Rayaldee Phase 3 Clinical Trial Results Presented at American Society of Nephrologists Meeting
   Clinical Trial for Rayaldee as Adjunctive Cancer Therapy Began in Q4 2014
   Marketing for 4Kscore® Blood Test to Identify Risk of Aggressive Prostate Cancer in the US and Europe Began During 2014 and in Mexico in January 2015
   Two Papers Supporting 4Kscore Blood Test in European Urology Published
   Rolapitant™ NDA Submitted by OPKO Licensee, TESARO; Accepted for Review by FDA with a PDUFA date of September 5, 2015; OPKO Received $5 Million of $121 Million Total Potential Up Front and Milestone Payments
   Investigational New Drug (IND) Application for Long Acting Factor VIIa-CTP for Hemophilia Filed and Accepted in Q1 2015
   Clinical Studies for Long Acting Oxyntomodulin for Obesity and Diabetes Expected to Begin During 2015

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its fourth quarter ended December 31, 2014.  

OPKO verkündet viertes Viertel-Betriebs- und Finanzergebnisse


https://translate.google.de/...lts-5297414&edit-text=&act=url  

Die Vereinbarung mit Pfizer ist erst im Januar abgeschlossen: und somit sollte sie gar nicht in der Bilanz aufgeführt sein ...

Pfizer Kooperationsvereinbarung für Long Acting Human Growth Hormone Geschlossen in Januar 2015; OPKO Erhaltene Vorauszahlungen in Höhe von insgesamt $ 295.000.000 für die globale Vermarktung von hGH-CTP

financial results for its fourth quarter ended December 31


Wir glauben, dass OPKO die liquiden Mittel von $ 96.900.000 zum 31. Dezember 2014 zusammen mit dem $ 295,0 Millionen in Vorauszahlungen von Pfizer im Jahr 2015 erhalten haben, bieten OPKO mit ausreichend Liquidität, um die Entwicklung der Produktkandidaten weiter.  

aber nicht panisch

14.56
-0.28 (-1.89%)
After Hours: 14.25 -0.31 (-2.13%)
Feb 27, 6:28PM EST  
NYSE real-time data - Disclaimer
Currency in USD
 

OPKO Health's (OPK) CEO Phillip Frost on Q4 2014 Results - Earnings Call Transcript
Mar. 2, 2015 1:22 PM ET  |  About: OPKO Health, Inc. (OPK)

Operator

http://seekingalpha.com/article/...4-results-earnings-call-transcript

Greetings, and welcome to the OPKO Health Fourth Quarter 2014 Financial Results. At this time all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Steve Rubin, Executive Vice President of Administration for OPKO. Thank you, Mr. Rubin. You may now begin.
Steven Rubin - Executive Vice President, Administration

Thank you, and good morning. Before we begin, I'd like to remind you that any statements made during this call, which are historical will be considered forward-looking, and as such will be subject to risk and uncertainties, which could materially affect our expected results, including without limitation the various risks described in our Annual Report on Form 10-K for the year ended December 31, 2014 and our subsequent filings with the SEC.

I'd like to discuss the format for today's call. Adam Logal, our Chief Financial Officer will first talk about our financial results for the quarter. Charlie Bishop, the CEO of our Renal Division will then provide a brief update on our Rayaldee development program; followed by David Okrongly, President of our Diagnostics Division, who will provide an update of our diagnostics projects; and Dr. Frost will follow-up with a brief wrap up. We have the entire team here including Dr. Gilly Hart [ph] Head of Clinical Development for OPKO Biologics. He is with us to answer any questions you might have after our remarks.

With that, I'll turn it over to Adam Logal, our CFO.
Adam Logal - Senior Vice President and Chief Financial Officer

Thank you, Steve, and good morning, everyone. 2014 was an important year for us with our investments in R&D having begun turning [ph] in to commercial opportunities. In the first quarter of 2014, we successfully validated and launched the 4Kscore test in the U.S. launching in Europe in September and Latin America through the launch in Mexico last month.

Our investments in Rayaldee resulted in the completion of two successful Phase 3 clinical trials with the NDA filing coming shortly. Finally, in December we entered into an agreement with Pfizer which allows us to have a global commercial partner for our hGH-CTP product.

The $295 million in cash we received – from Pfizer in addition to the cash already on hand on our balance sheet puts us in the strongest financial position we’ve been in today.

In June, we successfully converted approximately $75 million of our convertible debt, leaving us with approximately $87 million of convertible debt outstanding as of December 31, 2014.

OPKO's pharmaceutical operating units continue to show positive results during the three months and for the full year 2014, with increases of $1 million and $8.8 million in year-over-year product revenue growth, principally being driven by our growth at FineTech our API manufacturer and our Spanish based business.

Pharmaceutical product revenue grew, despite foreign currency pressure impacting our Latin American businesses in comparison to the 2013 periods.

Total revenue for the three months ended December 31, 2014 were $25.5 million and $91.1 million compared to $20.7 million and $96.5 million for the comparable periods of 2013. The 2013 annual period included non-recurring licensing revenue of $16.3 million related to the 2013 transactions with Pharmsynthez and RXi.

The 2014 annual period included the milestone payment received under our license agreement with TESARO, as a result of their successful NDA submission.

Turning to our operating expenses, we had several events during the period that I would like to highlight. As a result of our successful Phase 3 clinical trials for Rayaldee, our net loss for the three months and year ended December 31, 2014 reflects an increase in the valuation of our contingent consideration payable to the sellers of Cytochroma.

 

Date Firm                             Action        From        To
Mar 2015 Oppenheimer Downgrades Outperform Perform

Read more: http://www.benzinga.com/analyst-ratings/...ons-too-high#ixzz3TLiAGGwj